InMed Pharmaceuticals Inc
INM
Company Profile
Business description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer’s disease, INM-089’s pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Contact
885 West Georgia Street
Suite 1445
VancouverBCV6C 3E8
CANT: +1 604 669-7207
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2025
Employees
13
Stocks News & Analysis
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,456.80 | 15.00 | -0.18% |
| CAC 40 | 7,423.67 | 15.03 | 0.20% |
| DAX 40 | 20,271.33 | 138.48 | 0.69% |
| Dow JONES (US) | 42,518.28 | 221.16 | 0.52% |
| FTSE 100 | 8,201.54 | 22.65 | -0.28% |
| HKSE | 19,260.17 | 40.39 | 0.21% |
| NASDAQ | 19,044.39 | 43.71 | -0.23% |
| Nikkei 225 | 38,444.58 | 29.72 | -0.08% |
| NZX 50 Index | 12,943.57 | 59.19 | 0.46% |
| S&P 500 | 5,842.91 | 6.69 | 0.11% |
| S&P/ASX 200 | 8,213.30 | 17.70 | -0.22% |
| SSE Composite Index | 3,227.12 | 13.82 | -0.43% |